BRCA2 and prostate cancer: The VUS p.Met2775Arg (c.8324 T > G) in BRCA2 was identified in one BC patient in double heterozygosis with other associated variants such as p.Arg137Gln in CHEK2 and p.Val717Met in PMS2. p.Met2775Arg has been described in prostate cancer cases and is characterized as possibly pathogenic by 4 in silico prediction tools despite this variant not affecting conversed residue [83, 84].